Trials / Unknown
UnknownNCT04727294
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- HealthTree Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.
Conditions
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Monoclonal Gammopathy of Undetermined Significance
- Coronavirus
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Questionnaire | Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. |
Timeline
- Start date
- 2021-01-22
- Primary completion
- 2021-09-01
- Completion
- 2021-12-01
- First posted
- 2021-01-27
- Last updated
- 2021-08-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04727294. Inclusion in this directory is not an endorsement.